Zymfentra (Infliximab-Dyyb) Patent Expiration, LOE Window & CMS Spending

Zymfentra (Infliximab-Dyyb) by Celltrion: Biologic BLA (Purple Book Regime), 0 AB generics, $988K 2024 CMS Part D & Medicaid spend, and $6,181 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCelltrion
FDA Application & PathwayB761358 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$988K
2024 Medicare Part D Spend$222K
2024 Medicaid Spend$766K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,181 intro WAC)